Loading…
Cycle Pharmaceuticals develops and launches treatments for rare diseases with a strong focus on patients and their caregivers. It operates Cycle Vita, a patient hub offering clinical support, dietary guidance, trial access, and a Free Goods Programme to help eligible patients get medicines. The company expands access through US product launches across conditions like PKU, MS, HAE, AKU, cystinuria, and PPP, underpinned by ongoing patient advocacy and support.
AI named Cycle Pharma in December 2025.